Cargando…

Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: A multi-center retrospective observational study

BACKGROUND: Since the risk of recurrence of venous thromboembolism (VTE) increases with duration or inadequate anticoagulation dosage, a proper regimen of apixaban and rivaroxaban is essential in patients with VTE, especially during the acute phase. This study aims to describe the clinical character...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al Yami, Majed S., Qudayr, Asma H., Alhushan, Lina M., Hakami, Fatemah M., Korayem, Ghazwa B., Alshaya, Omar A., Almohammed, Omar A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415217/ https://www.ncbi.nlm.nih.gov/pubmed/37576856 http://dx.doi.org/10.1016/j.jsps.2023.06.006

Ejemplares similares

Real-World Evaluation of the Safety and Effectiveness of Apixaban & Rivaroxaban Lead-in Dosing Compared to Parenteral Lead-in Dosing in the Treatment of Venous Thromboembolism: A Multi-Center Retrospective Cohort Study
por: Korayem, Ghazwa B, et al.
Publicado: (2023)

Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study
por: Alshaya, Omar A., et al.
Publicado: (2022)

Real-World Effectiveness and Safety of Apixaban versus Warfarin in Patients with Acute Venous Thromboembolism: Experience of a Large Tertiary Hospital in Saudi Arabia
por: Al Yami, Majed S, et al.
Publicado: (2021)

Safety and effectiveness of thromboprophylaxis use in hospitalized elderly medical patients at a Saudi tertiary care center
por: Korayem, Ghazwa B., et al.
Publicado: (2021)

The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: a meta-analysis and review of the guidelines
por: Alsubaie, Norah S., et al.
Publicado: (2021)

The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study
por: Korayem, Ghazwa B., et al.
Publicado: (2022)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
por: Reda, Sara, et al.
Publicado: (2022)

Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
por: Caroti, Kimberly Snow, et al.
Publicado: (2023)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study
por: Sindet-Pedersen, Caroline, et al.
Publicado: (2017)

Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date
por: Trkulja, Vladimir
Publicado: (2016)

Apixaban/tocilizumab interaction: Venous thromboembolism: case report
Publicado: (2021)

Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies
por: Wu, Olivia, et al.
Publicado: (2022)

Transferability of Published Population Pharmacokinetic Models for Apixaban and Rivaroxaban to Subjects with Obesity Treated for Venous Thromboembolism: A Systematic Review and External Evaluations
por: Leven, Cyril, et al.
Publicado: (2023)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
por: Hendriks, Stephan V., et al.
Publicado: (2020)

Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020)

Correction: Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2016)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia
por: Sattler, Laurent, et al.
Publicado: (2023)

Measurement of rivaroxaban and apixaban in serum samples of patients
por: Harenberg, Job, et al.
Publicado: (2014)

Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis
por: Cohen, A. T., et al.
Publicado: (2015)

Simulation-Based Education Implementation in Pharmacy Curriculum: A Review of the Current Status
por: Korayem, Ghazwa B, et al.
Publicado: (2022)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)

Effectiveness and safety of low-dose versus standard-dose rivaroxaban and apixaban in patients with atrial fibrillation
por: Perreault, Sylvie, et al.
Publicado: (2022)

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
por: Werth, Sebastian, et al.
Publicado: (2012)

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
por: Zalpour, Ali, et al.
Publicado: (2014)

D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study
por: Palareti, Gualtiero, et al.
Publicado: (2022)

Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects
por: de Jong, Lisa A., et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements
por: Meihandoest, Tamana, et al.
Publicado: (2021)

Thrombolytic therapy in cardiac arrest caused by cardiac etiologies or presumed pulmonary embolism: An updated systematic review and meta‐analysis
por: Alshaya, Omar A., et al.
Publicado: (2022)

Chemical versus Mechanical and Chemical Venous Thromboembolism Prophylaxis in Neurocritically Ill Patients: A Cohort Study
por: Alshaya, Abdulrahman I, et al.
Publicado: (2023)

Comparison between standard Vs. Escalated dose venous thromboembolism (VTE) prophylaxis in critically ill patients with COVID-19: A two centers, observational study
por: Aljuhani, Ohoud, et al.
Publicado: (2022)

Rivaroxaban for the treatment of venous thromboembolism in real life: A single-center prospective study
por: Demelo-Rodríguez, Pablo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_793nnl8pk682pl67cn8ljso0j3